Articles tagged "Epstein-Barr virus (EBV)"

2021 American Transplant Congress
Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant
S. Prockop¹, L. Gamelin², R. Dinavahi², Y. Sun², N. Guzman-Becerra², H. Parmar²
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Atara Biotherapeutics, South San Francisco, CA
*Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…
2021 American Transplant Congress
T-Cell Exhaustion in EBV DNAemic Solid Organ Transplant Recipients
S. Kothari, T. Ku, D. Kumar, A. Humar, V. H. Ferreira
Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: In transplant recipients, disease severity after infection with Epstein-Barr virus (EBV) may range from asymptomatic DNAemia to PTLD. Host factors likely play a key…
2020 American Transplant Congress
Impact of Immunosuppression Protocol on the Incidence of EBV Viremia and PTLD in Pediatric Kidney Transplant Recipients: A Single Center Experience
K. Bowers¹, V. M. Panzarino¹, A. Campos¹, J. Buggs², V. D. Bowers²
¹Pediatrics, USF, Tampa, FL, ²Transplant Surgery, TGH, Tampa, FL
*Purpose: The purpose of this study was to evaluate the efficacy of an immunosuppression protocol change, which included avoidance of anti-thymocyte globulin for induction and…
2020 American Transplant Congress
Belatacept Conversion is Safe and Effective in Adolescent and Young Adult Kidney Transplant Recipients
A. Moudgil, C. Petyak, K. Sgambat
Nephrology, Children's National Med. Ctr., Washington, DC
*Purpose: Though tacrolimus (TAC) is a cornerstone of maintenance immunosuppression in kidney transplant recipients, some patients have significant side effects related to TAC. Conversion from…
2020 American Transplant Congress
Sequence Variations of the LMP1 Protein are Detected in Pediatric Transplant Recipients and May Increase the Risk of EBV Disease
B. Mbiribindi¹, M. Arvedson¹, J. Pena¹, O. Hatton², C. Esquivel¹, O. Martinez¹, S. Krams¹
¹Department of Surgery/Division of Abdominal Transplantation, Stanford Univ School of Med, Stanford, CA, ²Molecular Biology, Colorado College, Colorado Springs, CO
*Purpose: Epstein-Barr virus (EBV) infects more than 90% of adults worldwide and is associated with several malignancies, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a…
2020 American Transplant Congress
Epstein-Barr Virus (EBV)+ Post-Transplant Lymphoproliferative Disorder (PTLD) is Associated with Tumor CCL3/CCL4 Expression and an Increase in Tumor-Infiltrating Monocytes
J. Toh¹, F. Vallania¹, W. A. Haynes¹, G. Bhagat², F. E. Craig³, S. H. Swerdlow⁴, T. Tousseyn⁵, S. M. Krams¹, P. Khatri¹, O. M. Martinez¹
¹Stanford University School of Medicine, Stanford, CA, ²Columbia University Medical Center, New York City, NY, ³Mayo Clinic College of Medicine, Phoenix, AZ, ⁴University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Katholieke Universiteit Leuven, Leuven, Belgium
*Purpose: PTLD is a serious post-transplant complication that encompasses a spectrum of abnormal lymphoproliferations, including B cell lymphoma-type PTLDs. Although many are EBV-driven, a significant…
2020 American Transplant Congress
Long-Term Safety in Epstein-Barr Virus (EBV)-Seropositive Kidney-Only Transplant Recipients Treated with Belatacept (BELA) in Clinical Practice: Final Study Results from the ENLiST Registry
C. Larsen¹, F. Vincenti², T. Kou³, C. Shadur⁴, B. Bresnahan⁵, S. Jordan⁶, E. S. Woodle⁷, N. Goes⁸, J. Vella⁹, D. Wojciechowski¹⁰, M. Polinsky³, A. Gomez-Caminero³
¹Emory University Transplant Center, Atlanta, GA, ²UCSF Transplant Center, San Francisco, CA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Iowa Kidney Physicians, Des Moines, IA, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷University of Cincinnati, Cincinnati, OH, ⁸Kaiser Permanente, San Francisco, CA, ⁹Maine Nephrology Associates, PA, Portland, ME, ¹⁰University Hospital Kidney and Liver Transplant Clinic, Dallas, TX
*Purpose: BELA, a selective T-cell costimulation blocker, is approved for the prophylaxis of organ rejection in EBV-seropositive adult kidney transplant recipients. In phase 3 BENEFIT…
2020 American Transplant Congress
Lifetime Survival Estimates Following Solid Organ Transplantation in the United States
C. Graham¹, M. Skeans², Y. Ahn², C. Watson³, A. Barlev⁴
¹RTI Health Solutions, Research Triangle Park, NC, ²Chronic Disease Research Group, Minneapolis, MN, ³Atara Biotherapeutics, South San Francisco, CA, ⁴Atara Biotherapeutics, Thousand Oaks, CA
*Purpose: The Scientific Registry of Transplant Recipients (SRTR) contains detailed patient and graft survival data for all solid organ transplants (SOT) in the United States…
2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
B. Shin, N. Ammerman, A. Vo, S. C. Jordan, M. Toyoda, S. Sethi
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…
2020 American Transplant Congress
Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte Precursors (EBV-CTLp) after Tab-cel Correlates with Response & Survival in Rituximab Relapsing or Refractory Ebv⁺ Posttransplant Lymphoproliferative Disease (PTLD)
R. Shen¹, N. Guzman-Becerra¹, Y. Sun¹, F. Forozan¹, S. Prockop², E. Doubrovina², R. O'Reilly², X. Li¹, M. Hiremath³, L. Gamelin¹, W. Navarro¹, B. Aftab¹
¹Atara Biotherapeutics, Thousand Oaks, CA, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Atara Biotherapeutics, South San Francisco, CA
*Purpose: EBV+ PTLD is often a fatal disease. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approximated…